In the field of urogynecology, synthetic polypropylene (PP) meshes have seen an increase in use over the last decade. These devices are implanted in over 200,000 women annually and are designed to restore pelvic organ support for women suffering from pelvic organ prolapse (1). Because they are essentially modified abdominal hernia meshes, their use in the field urogynecology has undergone little oversight. With more patients experiencing morbidity, the FDA has released two Public Health Notifications in 2009 and 2011 informing the public about the potential complications associated with urogynecological mesh implantation.

This content is only available via PDF.
You do not currently have access to this content.